

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America, the State of Israel or any jurisdiction other than Hong Kong.*

*Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.*

**FOSUN PHARMA**  
**复星医药**

上海復星醫藥（集團）股份有限公司  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 02196)

**FOSUN 复星**

復星國際有限公司  
**FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability)*

(Stock Code: 00656)

**JOINT ANNOUNCEMENT**

**THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF SISRAM MEDICAL LTD  
ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

**POST HEARING INFORMATION PACK**

The boards of directors of Fosun Pharma and Fosun International (the “**Boards**”) announce that they were informed by Sisram that in connection with the Proposed Spin-off and Listing, Sisram has submitted the Post Hearing Information Pack (the “**PHIP**”), which contains certain business and financial information relating to Sisram, to the Hong Kong Stock Exchange for publication on the Hong Kong Stock Exchange’s website. It is expected that the PHIP will be available for viewing and downloading from the Hong Kong Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) from 20 August 2017.

Shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that there is no assurance that the Proposed Spin-off and Listing will take place or as to when they may take place. If the Proposed Spin-off and Listing do not proceed for any reason, the Preferential Offering will not proceed. If the Proposed Spin-off and Listing proceed, the timetable for the Global Offering, including the Preferential Offering, will be set out in the Prospectus and in a further announcement to be made by Fosun Pharma and Fosun International.

## **1. Introduction**

Fosun Pharma refers to its announcements dated 29 June 2016, 31 August 2016 and 6 June 2017 (the “**Fosun Pharma Announcements**”) and the circular to its shareholders dated 15 July 2016 relating to the Proposed Spin-off and Listing. The Proposed Spin-off and Listing were approved by Fosun Pharma’s shareholders at the 2016 Second Extraordinary General Meeting held on 31 August 2016.

Fosun International refers to its announcements dated 6 June 2017 and 17 August 2017 (the “**Fosun International Announcements**”) relating to the Proposed Spin-off and Listing.

Unless the context otherwise requires, terms defined in the Fosun Pharma Announcements and Fosun International Announcements shall have the same meanings as those used in this announcement.

## **2. Post Hearing Information Pack**

The Boards announce that they were informed by Sisram that in connection with the Proposed Spin-off and Listing, Sisram has submitted the PHIP to the Hong Kong Stock Exchange for publication on the Hong Kong Stock Exchange’s website. It is expected that the PHIP will be available for viewing and downloading from the Hong Kong Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) from 20 August 2017.

The PHIP contains, among other things, certain business and financial information relating to Sisram. Shareholders and potential investors of Fosun Pharma and/or Fosun International should note that the PHIP is in draft form and the information contained in it is incomplete and is subject to change which can be material. Fosun Pharma and Fosun International do not have any obligation or liability whatsoever in relation to the PHIP.

## **3. General**

In connection with the Global Offering, the price of the Sisram Shares may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). Details of any intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) will be contained in the Prospectus.

The Boards wish to emphasize that the implementation of the Proposed Spin-off and Listing is subject to, among other things, the approval of the Hong Kong Stock Exchange and the final decisions of the Boards and of the board of directors of Sisram as to whether to proceed with the Proposed Spin-off and Listing, which are subject to market conditions and pricing. The Boards will only proceed with the Proposed Spin-off and Listing if the Boards consider that the price of the Sisram Shares which can be obtained in the Global Offering, which is subject to market

conditions, is such that proceeding with the Proposed Spin-off and Listing on those terms would be in the interests of Fosun Pharma and Fosun International and their respective shareholders as a whole.

**Shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that there is no assurance that the Proposed Spin-off and Listing will take place or as to when they may take place. If the Proposed Spin-off and Listing do not proceed for any reason, the Preferential Offering will not proceed. If the Proposed Spin-off and Listing proceed, the timetable for the Global Offering, including the Preferential Offering, will be set out in the Prospectus and in a further announcement to be made by Fosun Pharma and Fosun International.**

**Shareholders and potential investors of Fosun Pharma and/or Fosun International should exercise caution when dealing in or investing in the securities of Fosun Pharma and/or Fosun International. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.**

Further announcements will be made by Fosun Pharma and Fosun International in respect of the Proposed Spin-off and Listing as and when appropriate.

By order of the board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Chen Qiyu**  
*Chairman*

By order of the board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

20 August 2017

*As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.*

*As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetang, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.*

\* For identification purposes only